3 completed, 2 recruiting, 1 suspended, 1 unknown. 5 Phase 2, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Suspended 1 |
| Phase 3 | 2 | Recruiting 1, Suspended 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Somatostatin analog: new trials by email Literature Review of Somatostatin analog trials Research Report on Somatostatin analog
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial Somatostatin analog - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2 / Phase 3 | Recruiting | The Netherlands Cancer Institute | 39 | 2024-06-25 | 2025-03-03 |
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Somatostatin analog - Gastroenteropancreatic Neuroendocrine Tumor | Phase 4 | Recruiting | University Hospital, Antwerp | 270 | 2023-06-28 | 2024-06-14 |
| Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics Somatostatin analog - Pancreatic Diseases | Phase 2 / Phase 3 | Suspended | Mayo Clinic | 103 | 2020-11-17 | 2026-04-03 |
| Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia Somatostatin analog - Neuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL) | Unknown | University of Aarhus | 100 | 2020-09-01 | 2020-09-21 | |
| Octreotide LAR in the Induction of Immunologic Response in NENs Patients Octreotide Acetate - Neuroendocrine Tumors | Phase 2 | Completed | National Cancer Institute, Naples | 34 | 2017-06-28 | 2020-09-10 |
| A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Ramucirumab, Somatostatin Analog - Carcinoid Tumors | Phase 2 | Completed | Dana-Farber Cancer Institute | 43 | 2016-06-14 | 2025-02-19 |
| Phase II Study With ITF2984 in Acromegalic Patients Octreotide, ITF2984 500 mcg, ITF2984 1000 mcg - Acromegaly | Phase 2 | Completed | Italfarmaco | 48 | 2014-04-01 | 2016-06-16 |
Neuroendocrine Tumors (4) · Acromegaly (1) · Carcinoid Tumor (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Pancreatic Diseases (1)
Dana-Farber Cancer Institute (1) · Italfarmaco (1) · Mayo Clinic (1) · National Cancer Institute, Naples (1) · The Netherlands Cancer Institute (1) · University Hospital, Antwerp (1) · University of Aarhus (1)
Netherlands (3) · Italy (2) · United States (2) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Hungary (1) · Poland (1) · Romania (1) · Serbia (1) · Spain (1)
Jennifer A Chan, MD MPH (1) · Marc Peeters, MD (1) · Michael L Kendrick, MD (1) · Paolo Bettica, MD (1) · Salvatore Tafuto, MD (1)